Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.

Brockwell, Natasha K; Alamgeer, Muhammad; Kumar, Beena; Rivalland, Gareth; John, Thomas; Parker, Belinda S

Brockwell, Natasha K; Alamgeer, Muhammad; Kumar, Beena; Rivalland, Gareth; John, Thomas; Parker, Belinda S.

Afiliação

Brockwell NK; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Alamgeer M; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Kumar B; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.
Rivalland G; Department of Medical Oncology, Monash Medical Centre, Monash University, Clayton, Victoria, Australia.
John T; Monash Health, Clayton, Victoria, Australia.
Parker BS; Monash Health, Clayton, Victoria, Australia.

Transl Lung Cancer Res ; 9(3): 639-645, 2020 Jun.

Article em En | MEDLINE | ID: mdl-32676326

Palavras-chave

Immunotherapy; T cells; immune infiltrate; mesothelioma; sarcomatoid

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Transl Lung Cancer Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google